DeutschNewstral
Article
Mmarketwatch.com on 2020-10-06 14:01
Iovance's stock tumbles over questions about regulatory submission for melanoma drug
Related news
- BAmarin Stock Tumbles After Courtroom Lossbarrons.com
- MNovan stock tumbles on failed trialmarketwatch.com
- BAltria Stock Drops on Earnings, Regulatory Worrybarrons.com
- BInovio Stock Tumbles After Covid-19 Vaccine Trial Is Haltedbarrons.com
Akebia stock tumbles after FDA rejects anemia drugbizjournals.com- Iovance stock drops nearly 10% following snag with FDA over experimental melanoma treatmentbizjournals.com
- MBiogen's stock rises on submission to FDA for Alzheimer's drug applicationmarketwatch.com
- PInogen sees slight stock climb behind regulatory winspacbiztimes.com
- CLBT completes U.S. regulatory submissioncouriermail.com.au
- MAbbVie's stock tumbles after FDA warns on company's Hep C treatmentsmarketwatch.com
- MInnate Pharma's stock rallies 23% on leukemia drug submission in Europemarketwatch.com
- Aveo stock plunges after delay in FDA approval submission for cancer drugbizjournals.com
- MEndo's stock tumbles to 14 1/2-year low after drug maker swings to large lossmarketwatch.com
- MAltria's stock tumbles after Morgan Stanley turns bearish, slashes price targetmarketwatch.com
Gene mutation raises melanoma questionsNZ Herald- MAmerisourceBergen's stock tumbles after PharMEDium woes, downbeat outlook outweighs earnings beatmarketwatch.com
Castle Rock-based Riot Blockchain stock tumbles 30 percent after CNBC investigationDenver Post- MFacebook's stock tumbles againmoney.cnn.com
Questions being raised after Kodak’s stock has a big momentThe Fresno Bee